Left Ventricular Hypertrophy
Left ventricular hypertrophy (LVH) is an abnormal thickening of the wall of the left ventricle, the heart’s main pumping chamber. It is usually a response to a chronic increase in the work the heart has to do—most often from longstanding high blood pressure or aortic valve disease—but can also reflect genetic, infiltrative, or other heart muscle conditions. LVH increases the risk of heart failure, arrhythmias, and other cardiovascular complications. Imaging—particularly echocardiography and cardiac MRI—is used to identify and characterize LVH and help determine its cause.
What is it?
The left ventricle is the heart’s main pumping chamber, responsible for sending oxygen-rich blood through the aorta to the rest of the body. Its wall consists of three layers of muscle that contract together with each heartbeat. Left ventricular hypertrophy is an abnormal increase in the thickness of this muscular wall. While some thickening can occur as a healthy adaptation in athletes, most LVH identified clinically reflects a response to an underlying problem and is associated with increased cardiovascular risk.
The most common cause of LVH is longstanding high blood pressure (hypertension). When blood pressure is chronically elevated, the left ventricle must work harder to pump blood against increased resistance, and the muscle thickens in response. Aortic valve disease—particularly aortic stenosis, in which the valve becomes narrowed and the ventricle must generate higher pressure to push blood through it—is another important cause. Other contributors include chronic kidney disease, obesity, sleep apnea, and conditions associated with increased blood volume or vascular resistance.
LVH can also reflect specific heart muscle diseases. Hypertrophic cardiomyopathy (HCM) is a typically genetic condition characterized by abnormal thickening of the heart muscle—often the septum between the ventricles—and is one of the most common causes of sudden cardiac death in young people and athletes. Infiltrative diseases such as cardiac amyloidosis, sarcoidosis, and certain storage disorders can also produce thickening, often with characteristic features on imaging. Other genetic and congenital conditions can produce LVH as well.
LVH is also broadly classified by its pattern. Concentric hypertrophy involves uniform thickening of the wall with a normal or small cavity, often associated with pressure overload from hypertension or aortic stenosis. Eccentric hypertrophy involves increased ventricular size as well as wall thickening, typically associated with volume overload from valve regurgitation or other conditions. Asymmetric hypertrophy—particularly involving the septum—is characteristic of HCM.
Many people with mild LVH have no symptoms, particularly early in the condition. As LVH progresses, the thickened, less compliant ventricle may not fill properly between beats, leading to a condition called diastolic dysfunction (or heart failure with preserved ejection fraction). Symptoms may include shortness of breath (especially with exertion or when lying flat), fatigue, reduced exercise tolerance, palpitations, lightheadedness, fainting, chest discomfort, or leg swelling. LVH is also a risk factor for atrial fibrillation, ventricular arrhythmias, heart attack, stroke, and sudden cardiac death.
LVH is often first suggested by ECG, which may show certain voltage and pattern changes consistent with thickened muscle, though ECG alone is not sensitive or specific enough for diagnosis. Echocardiography is the primary imaging test for measuring left ventricular wall thickness, mass, chamber size, and function. Cardiac MRI provides highly accurate measurements, additional information about pattern and distribution, and tissue characterization (such as detection of fibrosis or specific patterns of late gadolinium enhancement) that can help distinguish between hypertensive heart disease, HCM, amyloidosis, and other causes. Blood biomarkers, ambulatory rhythm monitoring, and genetic testing (with appropriate counseling) may be added when inherited or infiltrative disease is suspected.
Important to Know
Management of LVH depends on the underlying cause. For LVH caused by hypertension, aggressive control of blood pressure with lifestyle changes and medications is the cornerstone of treatment and has been shown to reduce wall thickness over time and lower cardiovascular risk. Preferred medication classes—such as ACE inhibitors, ARBs, calcium channel blockers, and others—are tailored to individual factors and often address both blood pressure and additional cardiovascular goals.
When LVH is due to aortic stenosis or other significant valve disease, treatment of the valve—through surgical replacement, transcatheter aortic valve replacement (TAVR), or repair, as appropriate—often leads to favorable remodeling of the ventricle. Hypertrophic cardiomyopathy has specific management strategies, including beta-blockers and other medications, newer agents designed for obstructive HCM, septal reduction therapies (surgical myectomy or alcohol septal ablation) in selected patients, and specific guidance regarding exercise and arrhythmia risk. Cardiac amyloidosis and other infiltrative diseases require disease-specific treatments delivered in specialized centers.
Heart failure related to LVH is managed with guideline-directed medical therapy tailored to whether ejection fraction is preserved or reduced. Arrhythmias are treated with medications, ablation, or device therapy, and patients with significant arrhythmia risk may benefit from implantable cardioverter-defibrillators (ICDs).
Lifestyle measures benefit nearly all patients with LVH: not smoking, regular physical activity (with individualized guidance, especially for those with HCM or significant valve disease), a heart-healthy diet, weight management, limited alcohol, stress reduction, good sleep, and treatment of sleep apnea when present.
Family screening is an important consideration when an inherited cause is identified, such as HCM, certain infiltrative diseases, or specific genetic conditions. First-degree relatives may be advised to undergo clinical evaluation, imaging, and, when appropriate, genetic testing.
Care is typically coordinated by primary care clinicians and cardiologists, with input from heart failure or inherited cardiomyopathy specialists, electrophysiologists, interventional or structural cardiologists, cardiothoracic surgeons, and others as needed. Imaging findings are interpreted alongside symptoms, blood pressure measurements, and overall cardiovascular context rather than in isolation.
Red flag symptoms include severe or worsening shortness of breath, severe chest pain, fainting (especially with exertion), sustained rapid or irregular heart rate, signs of stroke, sudden weight gain, or signs of shock. These warrant prompt or urgent medical evaluation.